Danielle Valletti, Assistant Editor

This week's episode covers the first-ever joint guidelines for cardiovascular-kidney-metabolic syndrome, key highlights from ASCO 2026 and ADA 2026, and new FDA approvals in diabetes, infectious disease, and pain management.

New data from the phase 3 DeLLphi-304 trial suggest tarlatamab significantly improves intracranial efficacy outcomes, CNS progression-free survival, and overall survival in patients with relapsed small cell lung cancer (SCLC) and baseline brain metastases.

Chai Discovery’s collaboration with Eli Lilly highlights the growing role of AI in biologics discovery, leveraging generative AI models to accelerate design and optimization of novel therapeutic proteins and antibodies.

A pilot survey presented at ADA Scientific Sessions found that although health care professionals reported high awareness of DSMES, important gaps in actual understanding remain.

Real-world adoption of talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer highlights ongoing gaps in homologous recombination (HR) biomarker testing across prostate cancer care.

The FDA granted Priority Review to the NDA for bezuclastinib plus sunitinib in previously treated advanced gastrointestinal stromal tumors (GIST).

Real-world evidence is helping improve HER2-low metastatic breast cancer care, identify treatment gaps, and better understand patient distress and outcomes.

Findings from the SWOG S2001 trial show that pembrolizumab plus olaparib did not significantly improve progression-free survival compared with olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer harboring germline BRCA1/2 mutations.

Electronic patient-reported outcome (ePRO) monitoring platforms may improve symptom management, reduce hospitalizations, and help patients remain on cancer therapy longer through earlier intervention and continuous remote support.

GLP-1 receptor agonists may be associated with improved survival outcomes and lower recurrence rates among women with breast cancer, obesity, and type 2 diabetes.

Jessica Paulus, ScD, discusses emerging real-world evidence suggesting GLP-1 receptor agonists may be associated with improved survival outcomes across several cancer types while emphasizing the need for prospective clinical research.

APP-led benign hematology consult programs helped community oncology practices significantly reduce time to first appointment while strengthening interdisciplinary collaboration with pharmacists and physicians.

Emerging evidence links GLP-1 receptor agonists to improved breast cancer outcomes and the growing importance of metabolic health in survivorship care.

This interview discusses emerging immunotherapy trends at the 2026 ASCO Annual Meeting, including cancer vaccines, cell-based therapies, ADCs, and AI-driven immune profiling tools poised to reshape oncology care.

Proteomic liquid biopsy technology may improve early breast cancer detection, guide targeted therapy selection, and support longitudinal treatment monitoring in oncology care.

FDA approval brings durvalumab plus BCG to frontline high-risk NMIBC, boosting disease-free survival and expanding oncology options.

Pharmacists play a big role in biomarker testing, patient selection, and counseling on immune checkpoint inhibitor therapy in endometrial cancer.

Researchers discuss how GLP-1 receptor agonists may be associated with improved survival outcomes in breast cancer and what clinicians should consider as use of these therapies continues to grow.

Erin Zacholski, PharmD, BCOP, discusses the critical role of biomarker testing, immune checkpoint inhibitor selection, and pharmacist-led patient counseling in recurrent and metastatic endometrial cancer management.

Adding immune checkpoint inhibitors to carboplatin and paclitaxel has become the new frontline standard for advanced or recurrent endometrial cancer.

This week's episode covers the White House's expansion of the TrumpRx.gov platform, the pharmacist's critical role in closing adult hepatitis B vaccination gaps, and new FDA approvals in immunology, oncology, and cardiovascular care.

GLP-1 receptor agonists, molecular profiling, and biomarker-driven treatment strategies may help improve outcomes and personalize care for patients at risk for or diagnosed with endometrial cancer.

GLP-1 receptor agonists could influence endometrial cancer prevention, obesity management, fertility preservation, and molecularly guided treatment strategies in gynecologic oncology.

Heavy marijuana smoking may increase lung cancer risk, with cannabis use disorder linked to higher odds of small cell and non–small cell disease.

Emerging evidence surrounding GLP-1 receptor agonists and progestin therapies could influence preventive care strategies and endometrial cancer risk reduction in high-risk patients.

The FDA approved 2 new indications for fam-trastuzumab deruxtecan-nxki in HER2-positive early-stage breast cancer, expanding its use in both neoadjuvant and adjuvant settings.

FDA Recall targets True Metrix blood glucose monitoring systems after E-5 errors risk mistreating diabetes; updated guidance helps patients, pharmacists prevent harm.

A single dose of psilocybin produced rapid and clinically meaningful reductions in depressive symptoms in patients with major depressive disorder.

This week’s episode covers Marty Makary’s resignation as FDA commissioner, evolving hepatitis B vaccination efforts, and new FDA approvals in asthma and precision oncology.

A novel urine-based test outperformed mpMRI in detecting prostate cancer progression and may help reduce unnecessary biopsies.